KR20070035232A - 인 난포자극호르몬의 안정한 용액 제형 - Google Patents
인 난포자극호르몬의 안정한 용액 제형 Download PDFInfo
- Publication number
- KR20070035232A KR20070035232A KR1020050089853A KR20050089853A KR20070035232A KR 20070035232 A KR20070035232 A KR 20070035232A KR 1020050089853 A KR1020050089853 A KR 1020050089853A KR 20050089853 A KR20050089853 A KR 20050089853A KR 20070035232 A KR20070035232 A KR 20070035232A
- Authority
- KR
- South Korea
- Prior art keywords
- stimulating hormone
- follicle stimulating
- phosphorus
- formulation
- solution formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
- 약리학적 유효량의 인 난포자극호르몬(human Follicle Stimulating Hormone), 안정화제로서 글리신, 메티오닌, 비이온 계면활성제 및 인산염 완충용액을 포함하는 것으로 구성되어 있는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 인 난포자극호르몬은 천연 또는 유전자 재조합 난포자극호르몬인 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 비이온 계면활성제는 폴리솔베이트계 비이온 계면활성제나 폴록사머계 비이온 계면활성제 또는 이들의 혼합 형태의 계면활성제로 이루어진 군에서 선택되는 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 3 항에 있어서, 상기 비이온 계면활성제는 폴리솔베이트 20인 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 글리신은 0.1내지 10% (w/v)로 포함되어 있는 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 메티오닌은 0.01내지2.0% (w/v)로 포함되어 있는 것 을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 비이온 계면활성제는 0.001 내지 0.02% (w/v)로 포함되어 있는 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 인산염 완충용액의 염 농도는 1 mM 내지 50 mM이고, pH는 6.5내지 7.5인 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 1 항에 있어서, 상기 제형에는 방부제 및/또는 등장화제가 추가로 포함되어 있는 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
- 제 9 항에 있어서, 상기 방부제는 벤질알콜, 크레졸, 알킬파라벤 또는 이들의 혼합물이고, 상기 등장화제는 수용성 무기염 등장화제 및/또는 당알코올 등장화제인 것을 특징으로 하는 인 난포자극호르몬 용액 제형.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050089853A KR101105871B1 (ko) | 2005-09-27 | 2005-09-27 | 인 난포자극호르몬의 안정한 용액 제형 |
TW095132376A TW200735897A (en) | 2005-09-27 | 2006-09-01 | HFSH aqueous formulation |
SA06270332A SA06270332B1 (ar) | 2005-09-27 | 2006-09-19 | تكوين hFSF مائي |
PE2006001144A PE20070437A1 (es) | 2005-09-27 | 2006-09-21 | FORMULACION ACUOSA hFSH |
ES06798894T ES2345058T3 (es) | 2005-09-27 | 2006-09-25 | Formulacion acuosa de hfsh. |
BRPI0616300-9A BRPI0616300A2 (pt) | 2005-09-27 | 2006-09-25 | formulaÇço aquosa de hfsh |
JP2008532167A JP5364374B2 (ja) | 2005-09-27 | 2006-09-25 | hFSH水性製剤 |
DE602006014175T DE602006014175D1 (de) | 2005-09-27 | 2006-09-25 | Wässrige hfsh-formulierung |
CN2006800355835A CN101272764B (zh) | 2005-09-27 | 2006-09-25 | hFSH水制剂 |
PCT/KR2006/003811 WO2007037607A1 (en) | 2005-09-27 | 2006-09-25 | Hfsh aqueous formulation |
US12/066,190 US20110201554A1 (en) | 2005-09-27 | 2006-09-25 | Hfsh aqueous formulation |
GT200600431A GT200600431A (es) | 2005-09-27 | 2006-09-25 | Formulacion acuosa hfsh |
AU2006295570A AU2006295570B2 (en) | 2005-09-27 | 2006-09-25 | hFSH aqueous formulation |
RU2008111632/15A RU2407514C2 (ru) | 2005-09-27 | 2006-09-25 | Водные композиции чфсг |
TR2008/01968T TR200801968T2 (tr) | 2005-09-27 | 2006-09-25 | HFSH sulu formülasyon. |
EP06798894A EP1928413B1 (en) | 2005-09-27 | 2006-09-25 | Hfsh aqueous formulation |
AT06798894T ATE466570T1 (de) | 2005-09-27 | 2006-09-25 | Wässrige hfsh-formulierung |
ARP060104208A AR056538A1 (es) | 2005-09-27 | 2006-09-26 | Formulacion acuosa hfsh |
US15/146,250 US20160243242A1 (en) | 2005-09-27 | 2016-05-04 | Hfsh aqueous formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050089853A KR101105871B1 (ko) | 2005-09-27 | 2005-09-27 | 인 난포자극호르몬의 안정한 용액 제형 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070035232A true KR20070035232A (ko) | 2007-03-30 |
KR101105871B1 KR101105871B1 (ko) | 2012-01-16 |
Family
ID=37899985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050089853A KR101105871B1 (ko) | 2005-09-27 | 2005-09-27 | 인 난포자극호르몬의 안정한 용액 제형 |
Country Status (18)
Country | Link |
---|---|
US (2) | US20110201554A1 (ko) |
EP (1) | EP1928413B1 (ko) |
JP (1) | JP5364374B2 (ko) |
KR (1) | KR101105871B1 (ko) |
CN (1) | CN101272764B (ko) |
AR (1) | AR056538A1 (ko) |
AT (1) | ATE466570T1 (ko) |
AU (1) | AU2006295570B2 (ko) |
BR (1) | BRPI0616300A2 (ko) |
DE (1) | DE602006014175D1 (ko) |
ES (1) | ES2345058T3 (ko) |
GT (1) | GT200600431A (ko) |
PE (1) | PE20070437A1 (ko) |
RU (1) | RU2407514C2 (ko) |
SA (1) | SA06270332B1 (ko) |
TR (1) | TR200801968T2 (ko) |
TW (1) | TW200735897A (ko) |
WO (1) | WO2007037607A1 (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0813948B8 (pt) | 2007-07-10 | 2021-05-25 | Medy Tox Inc | composição líquida farmacêutica de toxina botulínica com estabilidade melhorada |
CN102007143B (zh) | 2008-01-09 | 2015-08-26 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的新型胰岛素衍生物 |
PL2249869T3 (pl) * | 2008-02-08 | 2012-02-29 | Theramex Hq Uk Ltd | Ciekły preparat FSH |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
AU2009312235B2 (en) | 2008-11-04 | 2014-01-16 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone |
PT2498801T (pt) | 2009-11-13 | 2018-05-02 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina |
RU2537239C2 (ru) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
CN102821782B (zh) * | 2010-02-12 | 2015-07-15 | 印塔斯生物制药有限公司 | 促卵泡激素的液体配制品 |
EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
ES2550357T3 (es) | 2011-08-29 | 2015-11-06 | Sanofi-Aventis Deutschland Gmbh | Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
WO2015075743A1 (en) * | 2013-11-12 | 2015-05-28 | Cadila Healthcare Limited | Formulation for gonadotropins |
EP3091964A1 (en) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
CA2932875A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN105960249B (zh) | 2014-01-09 | 2021-03-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
HUE062573T2 (hu) | 2014-12-12 | 2023-11-28 | Sanofi Aventis Deutschland | Glargin inzulin/lixiszenatid rögzített arányú készítmény |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
CN112566652A (zh) | 2018-06-25 | 2021-03-26 | Jcr制药股份有限公司 | 含有蛋白的水性液体制剂 |
CN115429751B (zh) * | 2022-09-21 | 2023-11-17 | 景泽生物医药(合肥)股份有限公司 | 一种人重组卵泡刺激素注射剂及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270057A (en) * | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
WO1996029095A1 (en) * | 1995-03-21 | 1996-09-26 | Applied Research Systems Ars Holding N.V. | Hcg liquid formulations |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
KR20010083126A (ko) * | 1998-07-23 | 2001-08-31 | 피터 지. 스트링거 | 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법 |
ES2208305T3 (es) * | 1999-04-08 | 2004-06-16 | Genentech, Inc. | Composicion basada en polipeptidos de carga opuesta.. |
US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
DK1441589T3 (da) * | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer |
AU2003217367B2 (en) * | 2002-02-08 | 2005-09-08 | Alkermes Controlled Therapeutics, Inc. | Polymer-based compositions for sustained release |
US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
CN1195069C (zh) * | 2002-11-28 | 2005-03-30 | 南京医科大学 | 人卵泡刺激素β亚基单克隆抗体的制备方法 |
BRPI0409532B8 (pt) * | 2003-04-02 | 2021-05-25 | Ares Trading Sa | composição farmacêutica líquida, artigo de fabricação, método de fabricação de composição farmacêutica e método de fabricação de artigo de fabricação |
US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
US20080311078A1 (en) * | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
PL2249869T3 (pl) * | 2008-02-08 | 2012-02-29 | Theramex Hq Uk Ltd | Ciekły preparat FSH |
-
2005
- 2005-09-27 KR KR1020050089853A patent/KR101105871B1/ko active IP Right Grant
-
2006
- 2006-09-01 TW TW095132376A patent/TW200735897A/zh unknown
- 2006-09-19 SA SA06270332A patent/SA06270332B1/ar unknown
- 2006-09-21 PE PE2006001144A patent/PE20070437A1/es not_active Application Discontinuation
- 2006-09-25 RU RU2008111632/15A patent/RU2407514C2/ru active
- 2006-09-25 GT GT200600431A patent/GT200600431A/es unknown
- 2006-09-25 TR TR2008/01968T patent/TR200801968T2/xx unknown
- 2006-09-25 DE DE602006014175T patent/DE602006014175D1/de active Active
- 2006-09-25 EP EP06798894A patent/EP1928413B1/en not_active Revoked
- 2006-09-25 AU AU2006295570A patent/AU2006295570B2/en active Active
- 2006-09-25 BR BRPI0616300-9A patent/BRPI0616300A2/pt not_active Application Discontinuation
- 2006-09-25 JP JP2008532167A patent/JP5364374B2/ja active Active
- 2006-09-25 WO PCT/KR2006/003811 patent/WO2007037607A1/en active Application Filing
- 2006-09-25 AT AT06798894T patent/ATE466570T1/de not_active IP Right Cessation
- 2006-09-25 US US12/066,190 patent/US20110201554A1/en not_active Abandoned
- 2006-09-25 ES ES06798894T patent/ES2345058T3/es active Active
- 2006-09-25 CN CN2006800355835A patent/CN101272764B/zh active Active
- 2006-09-26 AR ARP060104208A patent/AR056538A1/es not_active Application Discontinuation
-
2016
- 2016-05-04 US US15/146,250 patent/US20160243242A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1928413B1 (en) | 2010-05-05 |
CN101272764A (zh) | 2008-09-24 |
BRPI0616300A2 (pt) | 2011-06-14 |
TW200735897A (en) | 2007-10-01 |
JP2009509953A (ja) | 2009-03-12 |
KR101105871B1 (ko) | 2012-01-16 |
SA06270332B1 (ar) | 2011-01-15 |
WO2007037607A1 (en) | 2007-04-05 |
AU2006295570B2 (en) | 2012-08-30 |
DE602006014175D1 (de) | 2010-06-17 |
AR056538A1 (es) | 2007-10-10 |
ES2345058T3 (es) | 2010-09-14 |
TR200801968T2 (tr) | 2008-06-23 |
PE20070437A1 (es) | 2007-04-26 |
GT200600431A (es) | 2007-08-28 |
EP1928413A1 (en) | 2008-06-11 |
RU2407514C2 (ru) | 2010-12-27 |
US20160243242A1 (en) | 2016-08-25 |
US20110201554A1 (en) | 2011-08-18 |
JP5364374B2 (ja) | 2013-12-11 |
RU2008111632A (ru) | 2009-10-10 |
ATE466570T1 (de) | 2010-05-15 |
AU2006295570A1 (en) | 2007-04-05 |
CN101272764B (zh) | 2011-05-04 |
EP1928413A4 (en) | 2008-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101105871B1 (ko) | 인 난포자극호르몬의 안정한 용액 제형 | |
US10987399B2 (en) | Stable formulations for parenteral injection of peptide drugs | |
DE69813322T2 (de) | Flüssige gonadotropinhaltige Arzneimittel | |
KR101573773B1 (ko) | Fsh의 액체 포뮬레이션 | |
KR100858856B1 (ko) | 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물 | |
CA2037884C (en) | Stabilized gonadotropin containing preparations | |
RU2553375C2 (ru) | Жидкий состав фолликулостимулирующего гормона | |
US20050266087A1 (en) | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium | |
JP2003504346A (ja) | 成長ホルモン製剤 | |
ES2358330T3 (es) | Formulaciones farmacéuticas de fsh y/o lh líquidas o liofilizadas junto con el tensioactivo no iónico poloxámero 188 y un agente bacteriostático. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141217 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151204 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161212 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190107 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 9 |